Advanced Technology Research on drugs and vaccines against parasitic diseases
Abstract
This effort selects promising anti-parasitic drug candidates for treating malaria and leishmaniasis for testing in humans, prepares data packages required for FDA approval of testing in humans. Studies have shown that the malaria parasite can become resistant to existing drugs, which makes it necessary to continually develop new and more effective and safe treatments. This effort selects candidate vaccines for various types of malaria, including the severe form of malaria (Plasmodium falciparum) and the less severe but relapsing form (Plasmodium vivax), prepares technical data packages required for FDA approval of testing in humans and conducts testing of promising malaria vaccine candidates in humans. A malaria vaccine would minimize the progression and impact of drug resistance and poor Warfighter compliance with taking preventive anti-malarial drugs. In FY17 the Vaccines for Prevention of Malaria research area and the Drugs to Prevent/Treat Parasitic Diseases research area are merged into this task area titled Advanced Technology Research on drugs and vaccines against parasitic diseases.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2018
- Source ID
- a8c3dc7bf0bbf64653905e3f75b7d1ef